Učitavanje...
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries
BACKGROUND: The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-Any(M13→M25)) in the CYD14 (2–14-y-ol...
Spremljeno u:
| Izdano u: | Trans R Soc Trop Med Hyg |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8245293/ https://ncbi.nlm.nih.gov/pubmed/33369671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/trstmh/traa154 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|